Concerns about the stalemate between Greece and its creditors sent the markets down to a sharply lower close with the Dow tumbling 107 points to 17,791. Nasdaq fell 21 points to 5,029.

On the upside

Shares of Invuity (Nasdaq: IVTY) surged in its market debut.

Atara Biotherapeutics (Nasdaq: ATRA) exercised its exclusive option with Memorial Sloan Kettering Cancer Center to license certain clinical stage, allogeneic T-cell therapies.

Shares of Kythera Biopharmaceuticals (Nasdaq: KYTH) continued rising.
 
On the downside

Sangamo BioSciences (Nasdaq: SGMO) chief scientific officer Philip Gregory left the biopharmaceutical to join Bluebird Bio (Nasdaq: BLUE).

Investors locked in profits on Sage Therapeutics (Nasdaq: SAGE).

Profit taking weighed down shares of Caesars Acquisition (Nasdaq: CACQ).
 
In the broad market, declining issues outpaced advancers by a margin of more than 5 to 3 on the NYSE and by more than 7 to 5 on Nasdaq. The broader S&P 500 lost 9 points to 2084. Bitcoin added $4 to $237.